Most peptide marketing cherry-picks weak rodent data and bets you won't notice. The trick is simple: pull one positive animal study, lead the product page with it, skip the part where 35 of 36 BPC-157 studies were rodents and the lone human pilot was n=2. Once you've read 100+ peptide papers on PubMed, the pattern jumps off the page. There's a specific gap in peptide info online: between academic databases (UniProt, PDB, Peptipedia) that need a biochem degree to navigate, and vendor pages that exist to convert clicks. For a researcher, practitioner, or evidence-led self-experimenter, no single trustworthy reference has clinical-grade data density and vendor-neutral framing.
The Next Pep research library at /library sits in that gap. 60+ compounds, BPC-157, TB-500, Tirzepatide, Semaglutide, Ipamorelin, CJC-1295, Sermorelin, GHK-Cu, PT-141, Epitalon, MOTS-c, NAD+, Semax, Selank, Thymosin Alpha-1, and dozens more, each with molecular data, mechanism, PK, dosing, safety, and primary PubMed sources in one view. Free. No signup. No vendor sponsorship.
Key Takeaways
- —Academic peptide databases (UniProt, Peptipedia, PDB) hold >19,000 peptides but need specialised tooling to interpret. Vendor pages run commercial framing, not research-grade data.
- —The Next Pep library covers 60+ practitioner-relevant compounds on the same schema for each: molecular formula, CAS, MW, sequence, mechanism, PK, dosing, safety, and PubMed/PMID links.
- —Data is pulled from primary literature and cross-referenced against PubChem and PubMed. No vendor marketing copy enters the library.
- —Paste any vendor product URL to import a new peptide in 20-40 seconds. Our extractor pulls structured data from unstructured vendor pages automatically.
- —Free, browser-based, no signup, maintained by a researcher (not a vendor).
Three typical sources of peptide info, and why each one fails you in a different way.
The first result for "BPC-157" on Google is almost always a vendor product page. These are built for purchase conversion, not research comprehension. Standard ingredients:
What they don't usually carry at any real density: the CAS number, full amino acid sequence, species-specific half-life data, published trial citations with PMID, or explicit separation of preclinical vs human evidence. Vendor descriptions are a fine entry point but they're not a reference-grade source. The marketing copy is also where the cherry-picking lives, one positive rodent study cited as if it were Phase III.
UniProt, PubChem, Protein Data Bank, Peptipedia, these are the ground-truth sources. They carry the data. They also assume a specific user: a researcher who can translate a FASTA sequence into mechanism, who already knows which journals and study types matter for a given claim, and who has institutional access to paywalled primary literature.
For a practitioner trying to figure out whether BPC-157 is appropriate for a use case, UniProt's entry P98171 (BPC, the gastric juice protein precursor) is only useful once you already know what you're looking at. It's a reference tier, not a decision-support layer.
Reddit, Discord, Instagram, the various wellness forums all have large active peptide communities. The practical wisdom is real, people share dosing experiences, side effect reports, vendor comparisons, COA reads. But the epistemic problems are obvious: nothing is citation-backed, individual reports don't aggregate cleanly, and the most confident claims are often the least evidence-based. Anecdotally, the loudest voice in any thread is rarely the best-read one.
The gap that leaves: a clinical-grade, practitioner-oriented reference with citations, structured data, and vendor-neutral framing. That's what the Next Pep library is built for.
Every entry in a research-useful peptide database needs these fields. If any are missing, the database is closer to a product catalogue than a reference.
Identifier fields:
Mechanism fields:
Pharmacology fields:
Evidence fields:
Practical fields:
The Next Pep library populates all of these for its 60+ compounds. Where a field is unknown or unestablished, it's marked as such, not invented to look complete. Be honest about evidence depth: most peptides have fewer than 10 human studies, and the ones that exist are often poorly powered, n in the teens, no placebo arm, no PMC-deposited dataset.
Browse the full library at /library. A few things that separate it from the alternatives.
Every peptide page runs the same template: identifier → mechanism → PK → evidence → dosing → safety → regulatory. That consistency is what makes cross-peptide comparison possible (and what powers the comparison tool at /compare).
Every mechanism claim, every dosing protocol, every adverse event statement is traceable to a source. Inline markdown citations link straight to PubMed, PMC, PubChem, or the primary journal DOI. Not a vendor citation. Not a Reddit post. If you click a study link and land on a PMID, you can read the methods and judge the evidence yourself.
If you're researching a peptide that isn't in the library yet, a newly synthesised compound, a niche research tool, something you found on a vendor page, paste the vendor URL into the search bar. Our extractor pulls structured data from the page in 20-40 seconds:
This is unique. No other peptide research platform ingests arbitrary vendor URLs. It's particularly useful for obscure peptides where the only documentation lives on a specific vendor's page.
The library is editorially independent. Vendors don't pay for placement. We don't rank compounds by affiliate payouts. The comparison display order is deterministic (by selection order, not by commercial interest). The compound ordering you see is the compound ordering you picked.
Every compound in the library is built from three sources in priority order:
Vendor product pages are only used in the URL-import workflow, they populate a separate "vendor data" layer that's explicitly kept out of the comparison and primary display. Vendor copy never bleeds into the mechanism or dosing fields.
UniProt and PubChem are canonical reference databases for protein and chemical data, they're the ground truth. Next Pep layers practitioner-relevant data (dosing protocols, clinical evidence summaries, safety profiles, regulatory status) on top of that canonical data. Think of us as the decision-support layer for researchers and practitioners; UniProt/PubChem are the source-of-truth layer for biochemists.
Yes. Fully free, no signup, no paywall. Browse all 60+ compounds at /library. The comparison tool and dosing calculator are free too.
Monthly for compounds with active literature (new trial data, new systematic reviews). On-demand when significant new evidence publishes. Regulatory status changes (FDA compounding list updates, WADA list changes) get updated within a few days.
Specialised niche compounds and newly-synthesised research tools are the main gap. Use the URL-import workflow at /library, paste any vendor product URL and the compound is in the library inside a minute, then it's available in the comparison tool for you and everyone else.
Karl Vorwerg, founder and lead researcher. Content is technically reviewed against PubMed, PubChem, and primary clinical literature. See the About page for methodology and sourcing details.
This article is for research and informational purposes only. The compounds in the Next Pep library are, in most cases, not FDA-approved for human clinical use. Consult a licensed healthcare professional before considering any peptide protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.